Journal article
Authors list: Kreitman, Robert J.; Dearden, Claire; Zinzani, Pier Luigi; Delgado, Julio; Karlin, Lionel; Robak, Tadeusz; Gladstone, Douglas E.; le Coutre, Philipp; Dietrich, Sascha; Gotic, Mirjana; Larratt, Loree; Offner, Fritz; Schiller, Gary; Swords, Ronan; Bacon, Larry; Bocchia, Monica; Bouabdallah, Krimo; Breems, Dimitri A.; Cortelezzi, Agostino; Dinner, Shira; Doubek, Michael; Gjertsen, Bjorn Tore; Gobbi, Marco; Hellmann, Andrzej; Lepretre, Stephane; Maloisel, Frederic; Ravandi, Farhad; Rousselot, Philippe; Rummel, Mathias; Siddiqi, Tanya; Tadmor, Tamar; Troussard, Xavier; Yi, Cecilia Arana; Saglio, Giuseppe; Roboz, Gail J.; Balic, Kemal; Standifer, Nathan; He, Peng; Marshall, Shannon; Wilson, Wyndham; Pastan, Ira; Yao, Nai-Shun; Giles, Francis
Publication year: 2018
Pages: 1768-1777
Journal: Leukemia
Volume number: 32
Issue number: 8
ISSN: 0887-6924
eISSN: 1476-5551
DOI Link: https://doi.org/10.1038/s41375-018-0210-1
Publisher: Springer Nature [academic journals on nature.com]
Abstract:
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/ refractory HCL who had >= 2 prior systemic therapies, including >= 1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 mu g/kg intravenously on days 1, 3, and 5 every 28 days for <= 6 cycles. Blinded independent central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males; median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%) achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation (6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.
Citation Styles
Harvard Citation style: Kreitman, R., Dearden, C., Zinzani, P., Delgado, J., Karlin, L., Robak, T., et al. (2018) Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia, Leukemia, 32(8), pp. 1768-1777. https://doi.org/10.1038/s41375-018-0210-1
APA Citation style: Kreitman, R., Dearden, C., Zinzani, P., Delgado, J., Karlin, L., Robak, T., Gladstone, D., le Coutre, P., Dietrich, S., Gotic, M., Larratt, L., Offner, F., Schiller, G., Swords, R., Bacon, L., Bocchia, M., Bouabdallah, K., Breems, D., Cortelezzi, A., ...Giles, F. (2018). Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 32(8), 1768-1777. https://doi.org/10.1038/s41375-018-0210-1
Keywords
cladribine; ERADICATION; immunohistochemistry; MINIMAL RESIDUAL DISEASE; RITUXIMAB; TERM-FOLLOW-UP
